合作類型：技術(shù) 行業(yè)類別: 生物科學與健康 過期時間：2017年11月22日
兩家西班牙的研究機構(gòu)開發(fā)了一種免疫測定方式，能夠?qū)诜鼓庍M行量化測定來阻止血栓疾病，同時能夠延長前凝血酶時間，幫助更好的檢測病患。該機構(gòu)希望與能將此技術(shù)市場化的合作伙伴進行許可證協(xié)議合作。
Summary:
Two Spanish Institutions have developed an immunochemical method to detect and quantify oral coumarin anticoagulants used to prevent certain thromboembolic diseases, that complementing prothrombin time (PT) determination, enables to make a better monitoring of the patient.
Companies interested in the development of the assay and bring it to market under a license agreement are sought.
Details:
About 2% of population is under treatment with oral coumarin anticoagulants (OAs), such as warfarin or acenocoumarol. The main problems associated to these drugs are their narrow therapeutic window and their unpredictable dose-response relationship. Thus, there is a large inter and intraindividual variability, but also bioavailability is affected by factors such as age, diet, medications, etc, requiring a personalized adjust and correction of the dose along the treatment.
Current methods to adjust OAs dose are based on the determination of the prothrombin time (PT) expressed as the International Normalized Ratio (INR). Nevertheless, in many cases ideal INR, based only in pharmacodynamic facts is difficult to achieve, and complementarily, measurement of plasma concentrations of the OAs should be taken into account.
A new ELISA-test able to quantify plasmatic levels of acenocoumarol and warfarin is presented. This method is rapid, sensitive, allows routine monitoring and individual pharmacokinetic studies of these drugs, in contrast to other methods based on HPLC or GC-MS.
The immunoreagents produced do show high avidity for the coumarin OAs and could be used on different immunochemical analytical configurations, including ELISA microplates, test strips, immunosensors or any other format suitable for further implementation on Point-of-Care (PoC) devices.
In combination with the measurement of PT, this test could provide a complete profile of the drug level for better monitoring of the patient and their response to medication.
Type and Role of Partners Sought:
Pharma or biotech companies interested in diagnostics
Activity of the partner: diagnosis, blood coagulation
